John Rossi

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors.

Alteration of branch site consensus sequence and enhanced pre-mRNA splicing of an NMDAR1 intron not associated with schizophrenia.

Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells.

A nucleolar TAR decoy inhibitor of HIV-1 replication.

Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters.

Exposure assessment and the health of deployed forces.

Functional siRNA expression from transfected PCR products.

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.

Localized expression of small RNA inhibitors in human cells.

Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.

Biological and health effects of exposure to kerosene-based jet fuels and performance additives.

Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line.

Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages.

siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

Treatment of spontaneous and chemically induced EEG paroxysms in the Fischer-344 rat with traditional antiepileptic drugs or AED+CGP 35348 polytherapy.

Coupling of RNAi-mediated target downregulation with gene replacement.

Approaches for the sequence-specific knockdown of mRNA.

RNA-mediated inhibition of HIV in a gene therapy setting.

Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase.

Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.

In vivo detection of ribozyme cleavage products and RNA structure by use of terminal transferase-dependent PCR.

Construction and transfection of PCR products expressing siRNAs or shRNAs in mammalian cells.

Cyclophilin A is required for retinoic acid-induced neuronal differentiation in p19 cells.

Control of HIV-1 replication by RNA interference.

Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.

Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B).

RNAi applications in mammalian cells.

Gene expression profiles in the rat central nervous system induced by JP-8 jet fuel vapor exposure.

Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Ribozyme diagnostics comes of age.

Recent applications of RNAi in mammalian systems.

Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes.

Unlocking the potential of the human genome with RNA interference.

Therapeutic applications of RNA interference: recent advances in siRNA design.

Medicine: a cholesterol connection in RNAi.

Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA.

Uncoupling of RNAi from active translation in mammalian cells.

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.

Lentiviral vector delivery of recombinant small interfering RNA expression cassettes.

A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon.

Importance of public engagement found through involvement in horse slaughter bill.

Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells.

siRNA target site secondary structure predictions using local stable substructures.

Sensing the danger in RNA.

Comparative single-turnover kinetic analyses of trans-cleaving hammerhead ribozymes with naturally derived non-conserved sequence motifs.

Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.

Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages.

Helping RNAi deliver.

Amplification of RNAi--targeting HLA mRNAs.

Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells.

Current status of gene therapy strategies to treat HIV/AIDS.

Behavioral test methods workshop.

Receptor-targeted siRNAs.

Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells.

Martin Tabler, Ph.D. June 20, 1956-April 3, 2005.

A society of our own.

Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells.

RNAi and the P-body connection.

HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence.

Functional polarity is introduced by Dicer processing of short substrate RNAs.

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.

Approaches for chemically synthesized siRNA and vector-mediated RNAi.

Mammalian Dicer finds a partner.

Enhancing siRNA effects in T cells for adoptive immunotherapy.

The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells.

Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.

Antiviral applications of RNAi.

The diversity of RNAi and its applications.

RNAi as a treatment for HIV-1 infection.

Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro.

A nucleolar localizing Rev binding element inhibits HIV replication.

Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection.

Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.

Partnering aptamer and RNAi technologies.

Expressing short hairpin RNAs in vivo.

Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells.

Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi.

Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing.

Small interfering RNAs to the rescue: blocking L1 retrotransposition.

RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.

Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs.

Chemical modifications rescue off-target effects of RNAi.

Metalloproteases regulate T-cell proliferation and effector function via LAG-3.

Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication.

Transcriptional activation by small RNA duplexes.

Strategies for silencing human disease using RNA interference.

A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.

Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors.

Distance constraints between microRNA target sites dictate efficacy and cooperativity.

Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.

Rational design and in vitro and in vivo delivery of Dicer substrate siRNA.

Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells.

Epigenetics and microRNAs.

Optimization and characterization of tRNA-shRNA expression constructs.

RNAi therapeutics: principles, prospects and challenges.

Short hairpin RNA causes the methylation of transforming growth factor-beta receptor II promoter and silencing of the target gene in rat hepatic stellate cells.

Molecular medicine: entry granted.

Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.

Cloning and detecting signature microRNAs from mammalian cells.

Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations.

Targeted cleavage: tuneable cis-cleaving ribozymes.

MicroRNAs in disease and potential therapeutic applications.

Genetic therapies against HIV.

Expression strategies for short hairpin RNA interference triggers.

Principles of Dicer substrate (D-siRNA) design and function.

Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.

Tat-regulated expression of RNA interference: triggers for the treatment of HIV infection.

Realizing the promise of RNAi.

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

RNAi mechanisms and applications.

Wandering eye for RNAi.

Bivalent aptamers deliver the punch.

Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells.

Functional and intracellular localization properties of U6 promoter-expressed siRNAs, shRNAs, and chimeric VA1 shRNAs in mammalian cells.

Toward a zoocentric animal ethics.

MicroRNA-directed transcriptional gene silencing in mammalian cells.

A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs.

Designing and utilization of siRNAs targeting RNA binding proteins.

The promises and pitfalls of RNA-interference-based therapeutics.

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

Overview of gene silencing by RNA interference.

Nonhuman primate research: the wrong way to understand needs and necessity.

Dotting the I's and crossing the T's: integration analyses in transduced patient T cells.

Transcriptional gene silencing using small RNAs.

New hope for a microRNA therapy for liver cancer.

TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN.

Evidence for X-chromosomal schizophrenia associated with microRNA alterations.

SNPs in human miRNA genes affect biogenesis and function.

Problems associated with reporter assays in RNAi studies.

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Effect of saphenous vein diameter on closure rate with ClosureFAST radiofrequency catheter.

Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR.

The therapeutic potential of cell-internalizing aptamers.

Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.

Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.

CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs.

RNAi-based therapeutics-current status, challenges and prospects.

Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5.

Absence of functional EpoR expression in human tumor cell lines.

A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle.

Strategies in designing multigene expression units to downregulate HIV-1.

Aptamer-targeted cell-specific RNA interference.

Combinatorial latency reactivation for HIV-1 subtypes and variants.

Dual-targeting siRNAs.

Silencing of gene expression in cultured cells using small interfering RNAs.

International research and positive obligations: are they "transaction specific"?

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.

Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells.

Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

RNAi and small interfering RNAs in human disease therapeutic applications.

A role for human Dicer in pre-RISC loading of siRNAs.

Is equal moral consideration really compatible with unequal moral status?

Cell-specific aptamer-mediated targeted drug delivery.

OTS highlights advance in basic and translational aspects of oligonucleotide research.

An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.

Lentivirus transduction of hematopoietic cells.

Inducible and reversible breaching of the blood brain barrier by RNAi.

RNA nanoparticles come of age.

Progress in RNAi-based antiviral therapeutics.

Aptamer-targeted RNAi for HIV-1 therapy.

Stopping RNA interference at the seed.

Ex vivo gene therapy for HIV-1 treatment.

Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes.

Human brain EEG indices of emotions: delineating responses to affective vocalizations by measuring frontal theta event-related synchronization.

A boost for the emerging field of RNA nanotechnology.

A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.

Phylogenetic comparison of small RNA-triggered transcriptional gene silencing.

Current progress of siRNA/shRNA therapeutics in clinical trials.

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

MicroRNAs and their potential involvement in HIV infection.

Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Biogenesis and function of endogenous and exogenous siRNAs.

A bias-reducing strategy in profiling small RNAs using Solexa.

A novel nuclear miRNA mediated modulation of a non-coding antisense RNA and its cognate sense coding mRNA.

Interplay between HIV-1 infection and host microRNAs.

Lack of expression and function of erythropoietin receptors in the kidney.

The development of RNA interference therapeutics.

RNA-Based Therapeutics: Current Progress and Future Prospects.

Value-ladenness and rationality in health communication.

Screening Effective Target Sites on mRNA: A Ribozyme Library Approach.